Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, RNA editing gene therapy product for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback